Dextranomer/hyaluronic acid injections for patients with vesicoureteral reflux
Does the age at injection predict the outcome?
DOI:
https://doi.org/10.5489/cuaj.9150Keywords:
vesicoureteral reflux, endoscopic, urinary tract infections (UTI)Abstract
INTRODUCTION: We aimed to assess the impact of age of the initial dextranomer/hyaluronic acid (Dx/HA) injection on the subsequent outcome, including the need for repeated injections.
METHODS: The charts of patients who underwent Dx/HA injection from 2010-2020 were retrospectively reviewed. Two groups were created according to the number of Dx/HA injections: single vs. repeated injections. Patients who presented with antenatal hydronephrosis, neurogenic bladder, and followup less than one year after the first injection were excluded. Repeated Dx/HA injections were indicated in patients with documented vesicoureteric reflux (VUR) who experienced recurrent febrile urinary tract infection (fUTI) postoperatively.
RESULTS: A total of 172 patients with 189 renal units were included; 139 (73.5%) units underwent single injections, whereas 50 (26.5%) had repeated injections. Twenty-three (48.9%) patients with repeated injections presented before the age of one year vs. 24 (51.1%) after the age of one year (p=0.02). Of the repeated group, 34 (68%) units received two injections, 14 (28%) were injected three times or more, and two (4%) had other treatment modalities. Forty-four percent of units requiring repeated injections had high-grade VUR (grades 4 and 5), compared to only 22.3% of those successfully treated with a single injection (p=0.003).
CONCLUSIONS: In our cohort, 26.5% of renal units underwent repeated Dx/HA injections. Forty-four percent of units with repeated injections had grade 4-5 VUR. Patients with VUR who were injected or presented with fUTI before the age of one year old were at higher risk of repeated injections than those who were injected or presented later.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.
